The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
Abstract
Objective: Safer and more effective therapies are needed for the treatment of systemic lupus erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE. Methods: A phase I/II dose‐escalation trial of rituximab added to ongoing therapy in SLE was conducted. Rituximab was administered as a single infusion of 100 mg/m 2 (low dose), a single infusion of 375 mg/m 2 (intermediate dose), or as 4 infusions (1 week apart) of 375 mg/m 2 (high dose). CD19+ lymphocytes were measured to determine the effectiveness of B cell depletion. The Systemic Lupus Activity Measure (SLAM) score was used as the primary outcome for clinical efficacy. Results: Rituximab was well tolerated in this patient population, with most experiencing no significant adverse effects. Only 3 serious adverse events, which were thought to be unrelated to rituximab administration, were noted. A majority of patients (11 of 17) had profound B cell depletion (to <5 CD19+ B cells/μl). In these patients, the SLAM score was significantly improved at 2 and 3 months compared with baseline (P = 0.0016 and P = 0.0022, respectively, by paired t‐test). This improvement persisted for 12 months, despite the absence of a significant change in anti–double‐stranded DNA antibody and complement levels. Six patients developed human antichimeric antibodies (HACAs) at a level ≥100 ng/ml. These HACA titers were associated with African American ancestry, higher baseline SLAM scores, reduced B cell depletion, and lower levels of rituximab at 2 months after initial infusion. Conclusion: Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion. Based on these results, controlled trials of rituximab appear to be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway
Schiemann, B., Gommerman, J. L., Vora, K., Cachero, T. G., Shulga-Morskaya, S., Dobles, M., Frew, E., & Scott, M. L. (2001) · Science · doi:10.1126/science.1061964 · Cited by 1,069
Reciprocal regulation of polarized cytokine production by effector B and T cells
Harris, D. P., Haynes, L., Sayles, P. C., Duso, D. K., Eaton, S. M., Lepak, N. M., Johnson, L. L., Swain, S. L., & Lund, F. E. (2000) · Nature Immunology · doi:10.1038/82717 · Cited by 839
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus
Odendahl, M., Jacobi, A., Hansen, A., Feist, E., Hiepe, F., Burmester, G. R., Lipsky, P. E., Radbruch, A., & Dörner, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5970 · Cited by 642
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
From T to B and back again: positive feedback in systemic autoimmune disease
Shlomchik, M. J., Craft, J. E., & Mamula, M. J. (2001) · Nature Reviews Immunology · doi:10.1038/35100573 · Cited by 572
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
Avery, D. T., Kalled, S. L., Ellyard, J. I., Ambrose, C., Bixler, S. A., Thien, M., Brink, R., Mackay, F., Hodgkin, P. D., & Tangye, S. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18025 · Cited by 509
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Self-citationBåve, U., Magnusson, M., Eloranta, M.-L., Perers, A., Alm, G. V., & Rönnblom, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3296 · Cited by 380
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death.
Abu‐Shakra, M., Urowitz, M. B., Gladman, D. D., & Gough, J. (1995) · PubMed · Cited by 376
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Funk, J. L., Cordaro, L. A., Wei, H., Benjamin, J. B., & Yocum, D. E. (1998) · Journal of Clinical Investigation · doi:10.1172/jci728 · Cited by 332
Chan, O., & J. Shlomchik, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.51 · Cited by 306
The central and multiple roles of B cells in lupus pathogenesis
Chan, O. T. M., Madaio, M. R., Shlomchik, M. J., Chan, O. I. M., Madaio, M. P., & Shlomchik, M. J. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01310.x · Cited by 281
B Lymphocytes Regulate Dendritic Cell (Dc) Function in Vivo
Moulin, V., Andris, F., Thielemans, K., Maliszewski, C., Urbain, J., & Moser, M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.475 · Cited by 261
Arce, E., Jackson, D. G., Gill, M. A., Bennett, L. B., Banchereau, J., & Pascual, V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.2361 · Cited by 252
B cells process and present lupus autoantigens that initiate autoimmune T cell responses.
Mamula, M. J., Fatenejad, S., & Craft, J. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.3.1453 · Cited by 229
Rahman, Z. S., Rao, S. P., Kalled, S. L., & Manser, T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030495 · Cited by 228
A Critical Role for B Cells in the Development of Memory CD4 Cells
Linton, P.-J., Harbertson, J., & Bradley, L. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5558 · Cited by 219
Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Wofsy, D., & Seaman, W. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3247 · Cited by 211
Sobel, E. S., Katagiri, T., Katagiri, K., Morris, S. C., Cohen, P. L., & Eisenberg, R. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1441 · Cited by 193
Garred, P., Voss, A., Madsen, H., & Junker, P. (2001) · Genes & Immunity · doi:10.1038/sj.gene.6363804 · Cited by 190
Retention of B-cell-specific monoclonal antibodies by human lymphoma cells
Press, O., Howell-Clark, J., Anderson, S., & Bernstein, I. (1994) · Blood · doi:10.1182/blood.v83.5.1390.1390 · Cited by 171
Ward, M. M., Marx, A. S., & Barry, N. N. (2000) · PubMed · Cited by 146
B cells as therapeutic targets for rheumatic diseases
Looney, R. J., Anolik, J. H., & Sanz, I. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00003 · Cited by 115
Self-citationSkok, J. A., Poudrier, J., & Gray, D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4284 · Cited by 112
Reininger, L., Winkler, T. H., Kalberer, C. P., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.3.853 · Cited by 111
Zhu, L. P., Cupps, T. R., Whalen, G., & Fauci, A. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112922 · Cited by 106
Sobel, E. S., Mohan, C., Morel, L. M., Schiffenbauer, J., & Wakeland, E. K. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2415 · Cited by 105
Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)
D'Arcy, C. A., & Mannik, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1717::aid-art299>3.0.co;2-c · Cited by 96
Chang, W. L., van der Heyde, H. C., & Klein, B. S. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00191-9 · Cited by 65
Both risk alleles for FcγRIIA and FcγRIIIA are susceptibility factors for SLE: a unifying hypothesis
Magnusson, V., Johanneson, B., Lima, G., Odeberg, J., Alarcón-Segovia, D., & Alarcón-Riquelme, M. E. (2004) · Genes and Immunity · doi:10.1038/sj.gene.6364052 · Cited by 59
Maeda, T., Yamada, Y., Tawara, M., et al. (2001) · International Journal of Hematology · doi:10.1007/bf02982552 · Cited by 42
Cited by
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationImmune Regulatory Function of B Cells
Mauri, C., & Bosma, A. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074934 · Cited by 1,249
Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation
Chen, S., Sims, G. P., Chen, X. X., Gu, Y. Y., Chen, S., & Lipsky, P. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1634 · Cited by 1,119
Metadata
- Authors
- Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 50
- Issue
- 8
- Pages
- 2580-2589
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2089016290
- Cited by
- 776
- References
- 40
- FWCI
- 41.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.